Thymidylate synthase (TS) is an essential enzyme for the de novo synthesis of thymidylate and subsequently DNA synthesis. TS has been used as a target for cancer chemotherapy in the development of fluoropyrimidines such as 5-fluorouracil (5-FU) and 5-fluorodeoxyuridine and of novel folate-based TS inhibitors such as ZD1694 (Tomudex, Raltitrexed), ZD9331, LY231514 (ALIMTA, Pemetrexed), AG337 (Thymitaq, Nolatrexed) and AG331. Although TS has been considered as a target for chemotherapy, the precise mechanism by which TS inhibition leads to cell death is still not completely resolved. TS inhibition results in depletion of dTTP, an essential precursor for DNA, and an increase in dUTP. This results in the socalled thymine-less death due to misincorporation of dUTP into DNA; its excision, catalysed by uracil-DNA glycosylase, results in DNA damage. Both this imbalance in dTTP/dUTP and DNA damage can result in induction of downstream events, leading to apoptosis. On the other hand a specific interaction exists between oncogenes and TS, by binding of TS protein to the p53 and c-myc RNA, while wt p53 can also inhibit TS promotor activity. TS inhibition by either 5-FU or antifolates can also result in a depression of TS protein mediated inhibition of TS mRNA translation leading to induction of more TS protein synthesis, and p53 protein may further deregulate this process. These complex indirect and direct interactions between oncogenes and TS may have as yet unclear clinical implications, since most data are based on in vitro or in vivo studies and some results are contradictive. In some preliminary clinical studies evidence was postulated for a combined prognostic role for TS and p53. This knowledge should be used to design clinical studies with the aim to deliver effective treatment to potentially sensitive patients both in the adjuvant setting and in advanced stage disease.
Introduction
Thymidylate synthase (TS) is a cytosolic enzyme, with a dimeric structure composed of two identical units of approximately 38.5 kDA [1] . TS is a rate-limiting enzyme in pyrimidine de novo deoxynucleotide biosynthesis and is therefore an excellent target for chemotherapeutic strategies. TS plays a central role in DNA synthesis in the reductive methylation of deoxyuridine-5'-monophosphate (dUMP) to deoxythymidine-5'-monophosphate (dTMP). Another source of dTMP is the salvage of thymidine to dTMP catalysed by the cytosolic enzyme thymidine kinase I (TK1) or the mitochondrial TK2 [2] . The cosubstrate for TS is the reduced-folate cofactor, 5,10-methylenetetrahydrofolate (CH 2 THF), which forms a ternary complex with dUMP and TS. 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), the active metabolite of 5-fluorouracil (5-FU) competes with dUMP, and can form a ternary complex which does not dissociate readily because the methyl group cannot be transferred ( Figure 1 ). 5-FU is the most common chemotherapeutic agent for metastatic colorectal cancer. New antifolate TS inhibitors such as ZD1694 (Tomudex®, Raltitrexed), AG337 (Thymitaq, Nolatrexed®), LY231514 (MTA, multitargeted antifolate, ALIMTA, Pemetrexed®), GW1843U89, ZD9331, AG331, are in advanced stages of clinical development. These new antifolates have different properties with regard to folate transport, polyglutamylation and polyglutamylate accumulation and resistance patterns [3] . Their specific drug related characteristics have been reviewed recently [3, 4] .
TS inhibition leads directly to depletion of dTMP and subsequently of dTTP, and indirectly to an accumulation of dUMP. This will result in dUTP incorporation into DNA due to lack of the natural substrate dTTP. Besides the effects of direct inhibition, other aspects of cellular metabolism are also disturbed. Among them, the allosteric regulation of deoxycytidylate deaminase (dCMP deaminase) is lost; this enzyme usually functions at 2% of its capacity, due to activation by 2'-deoxycytidine-5'-triphosphate (dCTP) and feedback inhibition by dTTP [5] .
For 5-FU also other mechanisms of cytotoxicity have been described, such as incorporation of FdUTP and FUTP into DNA or RNA, respectively. The incorporation of the 5-FU metabolite FUTP in tumor cells is predominantly in the nuclear RNA compared to the other RNA subspecies [6] . Incorporation of the 5-FU metabolite FdUTP into DNA during DNA synthesis can result in miscoding and eventually into cell death. 5-fluorodeoxyribosyl residues can be cleaved and released from the DNA by Uracil-DNA glycosylase (UDG) leading to DNA SSB [7] . UDG is also under cell cycle control by E2F or PCNA [8, 9] . The UDG gene product was characterised as a cyclin-like enzyme with a PCNA binding domain and with down regulatory activity on E2F transcription, resulting in growth delay [8, 9] .
In recent years, studies on regulatory mechanisms of TS evaluated the increase in TS protein after treatment with fluoropyrimidines [10] [11] [12] [13] [14] [15] [16] [17] . In synchronised human mammary epithelial cells and human breast cancer cells, exposure to Raltitrexed resulted in a 40-fold increase in TS enzyme levels during the S-phase, without any change in TS mRNA level which was suggestive for a translational regulation of TS [10] . Chu et al. [13, 14] also found that 5-FU exposure to human colon cancer H630 cells resulted in induction of TS protein, which circumvented the cytotoxic effect. Binding of native TS protein to specific binding regions on TS mRNA results in a direct feedback inhibition of TS mRNA translation [15] [16] [17] . TS protein bound by FdUMP or an antifolate cannot bind to its own mRNA, leading to a decreased translation repression, and unregulated TS synthesis, possibly leading to resistance. TS upregulation in response to 5-FU or antifolates seems a general phenomenon, observed in many tumor cell lines, in vivo and in patients [12, 17] .
Recently it has also been reported that TS expression can also be regulated by tumor suppressor genes (e.g., p53 and c-myc) or oncogenes [17] . In this review we will discuss this regulation by p53 and relate them with downstream events specific for TS inhibition by 5-FU or antifolate TS inhibitors, leading to DNA damage and cell death.
TS inhibition and DNA damage as determinants of cytotoxicity
The alterations in expression of oncogenes or tumor suppressor genes in relation to DNA damage play an important role in the balance between cell death and growth arrest. The interaction between TS and DNA damage can occur at different levels: at the level of direct DNA damage by thymineless death inducing DNA strand breaks, and at the level of direct interaction between TS and tumor suppressor genes (e.g., p53) or repair genes.
Fluoropyrimidines (FdUrd and 5-FU) and antifolates (e.g., Raltitrexed, CB3717, AG331) are capable of inducing SSB and DSB [18] [19] [20] [21] , most likely by dTTP depletion. TS inhibition not only leads to a reduction in dTTP but also to an increase of dUTP as a consequence of dUMP accumulation. Deoxyuridine 5'-triphosphate nucleotidehydrolase (dUTPase) reduces the dUTP pools by degradation to dUMP ( Figure 2 ). Prolonged TS inhibition may lead to levels of dUTP eventually overwhelming dUTPase activity. Since DNA polymerase utilises dUTP and dTTP with equal efficiency, dUTP will be incorporated into DNA. UDG can remove the base uracil from the DNA, leaving an apyrimidinic site. When dUTP/dTTP pools are unbalanced, uracil (as dUTP) will be reinserted, and re-excised leading to DNA strand breakage and cell death [21] .
In TS-negative mutant FM3A cells, which depend on thymidine as a source for dTTP, thymidine deprivation resulted in SSB and DSB [22] . The DSB occurred at a specific site of the genome in contrast to ionising radiation which induces DSB in a random manner. When wild-type FM3A cells were incubated with FdUrd, depletion of dTTP and dGTP pools and an increase in the dATP pools was observed. The induction of DSB and cell death occurred at the same time, two hours after the highest deoxynucleotide imbalance was measured [23] , but the events leading from strand breaks to cell death were not characterized. Yin et al. [18] observed that 5-FU and FdUrd caused different DNA damaging effects in HCT-8 human colon cells. 5-FU did not induce DNA damage, even at 99% growth inhibitory concentrations, whereas FdUrd induced both SSB and DSB. FdUrd cytotoxicity correlated with DNA damage induced by TS inhibition, since thymidine could rescue FdUrd cytotoxicity [18] . In addition, Lonn et al. [24] demonstrated that 5-FU induced DNA lesions by two different mechanisms: the incorporation of metabolites into DNA, and the formation of DNA replication intermediates of high MW (10 Kb DNA), due to inefficient DNA repair by UDG. For FdUrd, only the second mechanism was responsible for its cytotoxic effect. However, in the human colon cancer GC 3 /cl cell line, 5-FU exposure resulted in both DNA SSB and DSB [25] . An increase in DNA strand breaks was observed when 5-FU was combined with leucovorin or interferon-oc2a [25] . Van der Wilt et al. [26] observed 25%-40% 5-FU-induced DSB in a panel of human and murine colon carcinoma cell lines, which was increased by the addition of interferon-a but not by interferon-y. These data are indicative for mechanistic interactions of 5-FU and interferon-a at the DNA level.
In human GC 3 /cl colon cancer cells and its TSm utant, dTTP depletion and increase in dATP were related to DNA damage and cytotoxicity [27] . From these TS" cells, a sub-population (Thy4) was derived, which was resistant to commitment to thymineless death. In these cells thymidine deprivation resulted in a Glarrest probably due to an altered essential checkpoint at the Gl-S boundary [28] . Thus it can be concluded that TS inhibition by fluoropyrimidines resulted in deoxynucleotide pool imbalance possibly leading to various types of strand breaks, while SSB sometimes but not always lead to DSB. DNA damage was related to cytotoxicity, a process in which control of essential cell cycle checkpoints seems important.
The antifolate CB3717 caused both mature and nascent DNA DSB in human lung carcinoma A549 cells [21] . Matsui et al. [29] demonstrated that cell cycle perturbation by Raltitrexed was not only related to DNA damage but also to the expression of p53/p2l. Cell cycle kinetics showed that S-phase arrest was essential for the induction of DNA damage, because drug treatment of synchronised cells in G2/M did not show any DNA damage. Since a wild-type (wt) p53 and a mutant (mt) p53 cell line were used, the presence ofp53 mutations did not seem to be important, however, DNA replication was necessary for DNA damage [29] . In HCT-8 cells the lipophilic antifolate AG331 was only able to induce DNA SSB and DSB in nascent DNA, whereas the polyglutamatable Raltitrexed induced both DNA strand break types in nascent and mature DNA. The damage of the mature DNA is likely a consequence of the inhibition of the DNA repair required after uracil misincorporation. Nascent DNA damage could be caused by postreplication error after misincorporation of dUTP at the replication fork. Thus, for damage to nascent DNA replication seems to be indispensable [20] .
DNA repair mechanisms in relation to fluoropyrimidine or antifolate sensitivity are not completely clear. In human colon adenocarcinoma cells FdUrd induced DNA lesions were enhanced by inhibition of calmodulin, which is important for cell proliferation but is not directly involved in DNA repair [30] . A calmodulinmediated system of DNA repair might be responsible for the increase in DNA strand breaks [30] . Differences in dUTPase may also play a role in repair of DNA SSB. FdUrd induced dUTP accumulation was lower in SW620 cells, which had a higher level of dUTPase compared to HT29 cells; this may explain the delayed induction of DSB in SW620 cells [31] . Transfection of E. coli dUTPase into HT29 cells resulted in a four to five-fold higher dUTPase level, leading to decreased DNA SSB and lower sensitivity to FdUrd [32] , possibly also because dUTPase can efficiently degrade FdUTP formed from FdUrd. These findings suggest the possible use of dUTPase to protect (e.g., by transfection) or increase (by inhibition of dUTPase) DNA damage.
TS and oncogene expression
There are indirect and direct interactions between TS and oncogenes. The direct interaction includes a regulation of TS mRNA translation by p53 protein; on the other hand TS inhibition mediated DNA damage can result indirectly in an increase of wt-p53 expression, and subsequently of p21, a cell-cycle kinase inhibitor [reviewed in [33] [34] [35] . This results in cell cycle arrest during which apoptosis or DNA repair can occur. Acti-vated wt p53 can also induce various targets including cyclin G, the damage response genes Gadd45 and ERCC3, and bax, a cell death promoting gene [33] [34] [35] . In a high percentage of human cancers this protection mechanism to DNA damage is disrupted through mutations inp53 [36] .
In both mouse embryonic and NIH-3T3 fibroblasts with functional p53, the occurrence of DNA strand breaks after 5-FU exposure resulted in increased p53 levels by activation of /?55-DNA binding [37, 38] . This effect was not related to TS levels and/or TS inhibition. However, thymidine deprivation resulted in apoptotic cell death of the TS deficient human colon cancer cell line GC3/TS, which is wtp53; its clone Thy4 with mut p53, did not die and was in cytostasis. p21 was not involved in the decision to die by apoptosis or necrosis, but in Thy4 cells delayed apoptosis was related to high Bax levels. Thy4 cells also had a high expression of Fas (Apo-1, CD95) and were more sensitive to apoptosis induced by an anti-Fas antibody [40] . This suggests the presence of a functional Fas-mediated apoptosis pathway in colon cancer cells. Fas expression may be regulated by wt-p53, since transfection of wt-p53 in mt-p53 WiDr colon cancer cells increased Fas expression and sensitized cells to Fas-mediated apoptosis [41] .
In addition to a role o(p53, the cell cycle regulatory Rb protein may also play a role in the cell death induced by thymidine deprivation. Raltitrexed treatment of human adenocarcinoma HCT-8 cells not only resulted in growth-inhibition related DNA fragmentation, increased p53 and p21 protein expression, but also of hypophosphorylated Rb and subsequent binding to E2F-1 [42] . Similarly, human sarcoma cell lines, defective for Rb protein were less sensitive to MTX and FdUrd, which was probably related to elevation of DHFR or TS mRNA levels, respectively. This was due to a regulatory deficiency of E2F binding to hypophosphorylated Rb protein, resulting in the increase of TS and DHFR proteins [43] .
In human colon cancer cell lines, 5-FU and antifolates (Raltitrexed, MTA and Nolatrexed®) exposure induced TS expression irrespective of the p53 status (mt or wt). TS inhibition resulted in DNA strand breaks in both types of cell lines, but no induction ofp53 and p21 was observed in mt p53 cells whereas p53 and p21 were induced in wt-type p53 [44, 45] . The ratio p53/p21 may play a role in TS expression and induction after drug exposure.
TS has direct interactions with p53 and c-myc at the mRNA level [46] . In human colon cancer cells it was shown that the TS ribonucleoprotein complex contains the C-terminal coding region of the c-myc mRNA, while the ra-acting element of c-myc is important for the interaction between TS and c-myc mRNA [46] . This interaction plays a role in regulation of cell cycle progression. When cells enter the Gl-phase, c-myc protein and mRNA increase and bind to free TS protein. Consequently, TS protein cannot inhibit the translation of its own mRNA, resulting in an increase of newly synthesised TS protein. Only in the late S-phase, TS protein is present in a sufficient concentration to bind to its own mRNA and to that of c-myc, which results in a decrease of TS protein by an inhibition of the translation efficiency. TS protein can also form a complex with the protein-coding region of p53 mRNA, which is an important cw-acting binding site. TS protein can thus directly repress the translational efficiency of p53 mRNA [47] . The importance of c-myc and/755 proteins in the regulation of cell growth and proliferation warrants further evaluation of the biological relevance of the interactions of their mRNAs and that of TS at the post translational level not only in other cell lines (both cell-free systems and intact cells) but also in tumors.
In TS-deficient hamster V79 cells expressing the mouse TS gene other interactions between TS andp53 exist. Wt p53 inhibited the TS promoter activity to a high extent compared to mutant p53 transfected cells, but no specific sequence in the TS promoter region could be assigned for this inhibition. Lee et al. [48] suggested that p53 inhibited the TS promoter by sequestering one or more unidentified transcription factors.
In human leukemic cells the BCL-2 protein has been shown to be important for sensitivity to cytostatic drugs [49] . BCL-2 homodimers inhibit apoptosis, while bax promotes apoptotic cell death by forming heterodimers with BCL-2 [50] . The BCL-2 /bax ratio is essential in predicting whether a cell will die or not by apoptosis. Transfection of the BCL-2 gene into Burkitt's lymphoma cells [51] , decreased FdUrd and other TS inhibitors induced apoptosis from 67% in vector control cells to 8% in BCL-2 expressing cells. Cell cycle distribution, TS levels or activity were not influenced by BCL-2 transfection. BCL-2 may delay cell death due to appearance of sub-populations of cells with greater oncogenic potential or drug resistance [51] . In most human colon cancer cells, very low or no BCL-2 expression is present, and exposure to 5-FU, Raltitrexed or ALIMTA increased bax levels and induced DNA strand breaks at a drug concentration causing 50% inhibition. Apoptotic cell death was cell line-, time-and drug concentrationdependent [44, 45] .
Most of the above mentioned studies were carried out in selected in vitro systems. In Figure 3 a schematic representation on the role of p53 in relation to TS inhibition by 5-FU or Raltitrexed is depicted. The interaction between the downstream effects of TS inhibition and oncogene regulation is however much more complex in in vivo systems. In p53 BDF-1 knock-out mice 5-FU did not induce apoptosis in the intestinal crypts, while in wt p53 +/+ mice 5-FU induced apoptosis and p53 was upregulated. 5-FU-induced cell death was strictly related to RNA incorporation, since the administration of uridine inhibited cell death. Previously it was shown that delayed uridine administration specifically rescued RNA dependent mechanisms of 5-FU [53, 54] . Since thymidine rescued Raltitrexed-induced cell death, this effect was clearly related to TS-dependent mechanisms of cell death [51] . When combining these in vitro and in vivo data it is clear that the complexity of the whole process of drug induced cell death in relation toTS inhibition, cannot be described by a simple model valid for all cell and tumor types, such as leukemia and solid tumors [55] . p53 does not only have an important role in the context of general drug induced DNA damage but also in respect to its direct interaction with TS mRNA. TS inhibition possibly results in different direct or indirect interactions with tumor suppressor genes such asp53 or may even bypass p53 induced cell death. Although few data are known on BCL-2 in relation to TS inhibition the role of other oncogenes such as p21, bax and other members of the BCL-2 family such as BCL-x L needs to be elucidated [56] .
TS and oncogene expression in tumors from patients
Clinical studies on the possible relations between both TS and p53 expression in relation to treatment outcome are limited and usually small. In 36 patients with advanced colorectal cancer poor response to 5-FU-based chemotherapy was related to a high TS m-RNA expression and to a high incidence ofp53 mutations detected by sequencing andp53 protein expression [57] . A lowTS expression was also related to longer overall survival in these patients. In patients with wt p53 a significantly lower amount of TS mRNA was detected compared to patients with mt p53, suggesting a specific interaction between p53 and TS. In another group of untreated patients with stage II colon cancer, p53 overexpression and high TS expression levels were associated to higher recurrence rate and poorer survival [58] . In some smaller studies it was investigated whether tumors without p53 overexpression, with/727 expression and lowTS expression would respond to 5-FU-chemotherapy. However, the data obtained in small subsets of groups of 34 and 30 patients are insufficient to draw conclusions [59, 60] . In a larger group of 164 patients, overexpression of p53 and a high TS staining was related to a shorter disease-free survival, but did not predict efficacy of 5-FU-LV adjuvant therapy [61] . Similarly in another preliminary report no relation between p53 expression and response to 5-FU based chemotherapy was observed [62] .
It is evident that the development of new therapeutic strategies should be directed both towards drug-activated pathways (p53 and its downstream events) and specific drug targets such as TS. Different techniques are being used to detect TS or p53 levels. TS mRNA levels can be measured by RT-PCR, TS protein by immunohistochemistry using monoclonal or polyclonal antibodies, and the enzyme activity with a biochemical assay. Mt p53 gene integrity can be measured by gene sequencing, and p53 protein accumulation by immunohistochemistry or western blotting. The relation between p53 protein accumulation and frequency of mutations is not perfect and probably 20%-30% of p53 accumulations is due to other factors. So far it is unclear whether mRNA or protein levels are the most suitable to evaluate the prognostic or predictive value of TS. The discrepancy between the results of the above mentioned studies can be due to the inadequate use of detection methods. Since most clinical data are based upon patients with advanced colorectal cancer further attention needs to be given to less advanced stages of the disease (adjuvant treatment with TS inhibitors including 5-FU). So far few clinical data are available on TS and p53 regulation in early stage disease compared with advanced stage disease. Another factor which can influence the different results is the use of different treatment schedules.
Conclusions
The increased knowledge of the self-regulation of TS and its interaction with p53, directly at the molecular level, and as an indirect event, should be used to improve the therapeutic results, not only in colon cancer but also in other tumor types in which 5-FU is used. The new antifolate TS inhibitors may bypass some of the potential resistance mechanisms observed with 5-FU. Drug combinations may prevent an upregulation of TS, due to different binding of the drugs to TS and the potentially different type of DNA damage which is induced by either one of the specific TS inhibitors or by 5-FU. In addition there is increasing retrospective evidence from several groups that pretreatment TS levels may be related to the outcome of treatment of advanced disease. Measurement of TS levels, either by immunohistochemistry or RT-PCR, should enable us to select patients for TS-directed treatment, or in case of high TS give an alternative treatment such as irinotecan or oxaliplatin. In the course of these studies, the role of various oncogenes such as p53, but also that of Fas, should be included to determine their potential predictive value, either alone or in combination withTS.
